Literature DB >> 8059537

Prolonged presence of isoxsuprine in equine serum after oral administration.

G Pompa1, F Caloni, M Montana, C Pasqualucci.   

Abstract

1. Isoxsuprine [1-(4-hydroxyphenyl)-2-(1-methyl-2-phenoxyethylamino)-1- propanol] serum concentrations after single- and multiple-dose administration to horse were investigated using immunoenzymatic ELISA, HPLC-UV and thermospray HPLC-MS methods. 2. Using HPLC-MS, isoxsuprine was detected up to 72 h after a single administration (1.2 mg/kg by gastric probe) and up to 96 h after the end of serial administration (1.2 mg/kg every 12 h for 7 days). 3. ELISA detected the drug up to 96 h after a single dose and up to 6 days after the end of prolonged administration. 4. Isoxsuprine is present in horse serum almost totally in conjugated form very likely as glucuronide. 5. It is concluded the administration of this drug must be suspended much earlier than previously presumed if race horse antidoping tests for the drug are to be negative.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8059537     DOI: 10.3109/00498259409045897

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  3 in total

1.  Direct MS-MS identification of isoxsuprine-glucuronide in post-administration equine urine.

Authors:  J M Bosken; A F Lehner; A Hunsucker; J D Harkins; W E Woods; W Karpiesiuk; W G Carter; J Boyles; M Fisher; T Tobin
Journal:  Can J Vet Res       Date:  2000-04       Impact factor: 1.310

2.  Detection of beta 2-agonists in milk replacer.

Authors:  F Caloni; M Montana; C Pasqualucci; G Brambilla; G Pompa
Journal:  Vet Res Commun       Date:  1995       Impact factor: 2.459

3.  In vitro toxicity and formation of early conjugates in Caco-2 cell line treated with clenbuterol, salbutamol and isoxsuprine.

Authors:  A Stammati; P Badino; I De Angelis; G Re; O Vincentini; C Zanetti; F Zucco; G Brambilla
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1997 Apr-Jun       Impact factor: 2.569

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.